Characterization of Endothelial Progenitor Cell Interactions with Human Tropoelastin

Young Yu1,2,3, Steven G. Wise2,3,4*, Praveesuda L. Michael2,3, Daniel V. Bax4, Gloria S. C. Yuen2,3, Matti A. Hiob2,3,4, Giselle C. Yeo4, Ellysse C. Filipe2,3, Louise L. Dunn2,3, Kim H. Chan1,2,3, Hamid Hajian2,3, David S. Celermajer1,2,3, Anthony S. Weiss4,5,6‡, Martin K. C. Ng1,2,3‡

1 Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, 2050, Australia, 2 The Heart Research Institute, Sydney, NSW, 2042, Australia, 3 Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia, 4 School of Molecular Bioscience, University of Sydney, Sydney, NSW, 2006, Australia, 5 Bosch Institute, University of Sydney, Sydney, NSW, 2006, Australia, 6 Charles Perkins Centre, University of Sydney, Sydney, NSW, 2006, Australia

‡ These authors are joint senior authors on this work.
* wises@hri.org.au

Abstract

The deployment of endovascular implants such as stents in the treatment of cardiovascular disease damages the vascular endothelium, increasing the risk of thrombosis and promoting neointimal hyperplasia. The rapid restoration of a functional endothelium is known to reduce these complications. Circulating endothelial progenitor cells (EPCs) are increasingly recognized as important contributors to device re-endothelialization. Extracellular matrix proteins prominent in the vessel wall may enhance EPC-directed re-endothelialization. We examined attachment, spreading and proliferation on recombinant human tropoelastin (rhTE) and investigated the mechanism and site of interaction. EPCs attached and spread on rhTE in a dose dependent manner, reaching a maximal level of 56 ± 3% and 54 ± 3%, respectively. EPC proliferation on rhTE was comparable to vitronectin, fibronectin and collagen. EDTA, but not heparan sulfate or lactose, reduced EPC attachment by 81 ± 3%, while full attachment was recovered after add-back of manganese, inferring a classical integrin-mediated interaction. Integrin αVβ3 blocking antibodies decreased EPC adhesion and spreading on both N-terminal rhTE constructs N25 and N18 by 39 ± 3% and 56 ± 10%, respectively. In conclusion, rhTE supports EPC binding via an integrin mechanism involving αVβ3. N25 and N18 accounted for most of this interaction, accompanied by comparable spreading. In contrast, attachment and spreading on N10 was negligible. αVβ3 blocking antibodies reduced EPC spreading on both N25 and N18 by 45 ± 4% and 42 ± 14%, respectively. In conclusion, rhTE supports EPC binding via an integrin mechanism involving αVβ3. N25 and N18, but not N10 constructs of rhTE contribute to EPC binding. The regulation of EPC activity by rhTE may have implications for modulation of the vascular biocompatibility of endovascular implants.
Introduction

Circulating endothelial progenitor cells (EPCs) [1] are increasingly recognized to play an important role in cardiovascular regeneration. Increased levels of EPCs correlate with reduced risk of cardiovascular mortality [2] and contribute to angiogenesis, vasculogenesis [3] and the repair of injured vasculature [4]. EPCs are mobilized from the bone marrow and other sites in response to cytokines, growth factor stimulation, and ischemia [5]. EPCs have also shown therapeutic potential in vascular medicine. When EPCs were expanded \textit{ex vivo} and injected into pre-clinical models of hind limb ischemia [6] and myocardial infarction [7], a reduction in ischemia, improved limb salvage and myocardial function has been observed.

Accordingly, there is increasing interest in the potential for EPCs to facilitate re-endothelialization of endovascular prostheses such as stents following implantation in the vasculature [5]. The deployment of metallic stents results in significant injury to the vessel wall and disruption of the endothelium, predisposing them to thrombosis and neointimal hyperplasia from excessive smooth muscle proliferation [8]. Rapid re-endothelialization following vascular injury attenuates neointimal hyperplasia [9] while also deterring thrombus formation [10]. It is increasingly recognized that circulating EPCs substantially contribute to vascular prosthesis endothelialization [11,12], making them important mediators of implant compatibility. However, in animal models of induced vascular injury the use of pharmacological stimulation [13,14] or infusion of endothelial-like mononuclear cells has been met with variable success [15,16], perhaps reflecting the limitations of a systemic, less locally targeted approach.

Local enhancement and modulation of EPC activity at the site of injury is a potential strategy for improving the clinical efficacy of vascular implants. A range of sub-endothelial vascular matrix biomolecules have been shown to play critical roles in local regulation of thrombosis, endothelialization and smooth muscle cell proliferation, making these attractive candidates for modulation of vascular biocompatibility [17]. Elastin, an abundant elastic tissue protein, imparts both elasticity and important cell signaling. In elastin knockout mice, fatal arterial occlusive disease results from uncontrolled proliferation of vascular smooth muscle cells (VSMCs), suggesting a critical role for elastin in VSMC inhibition [18], consistent with recent \textit{in vitro} findings [19]. Elastin also promotes endothelial cell activity [20] while having low thrombogenicity [21]. These properties were mirrored when rhTE, the soluble pre-cursor of elastin was immobilized on metallic substrates, enhancing endothelial growth [22] and reducing thrombogenicity [23].

Elastin has several established modes of cell interaction, including via: 1) the elastin binding protein, which binds to GXXPG consensus sequences [24]; 2) cell surface glycosaminoglycans at the C-terminus [25] and; 3) the integrin \(\alpha V\beta3\), through the very last amino acids of the monomer, GRKRK [26]. These binding assays have predominantly been carried out using the elastin monomer, tropoelastin and fibroblasts. Recently, an additional integrin-mediated fibroblast binding site for tropoelastin has been described, encompassing domains 17 and 18, in the central region of the protein [27]. Tropoelastin interaction with endothelial cells appears to be somewhat different, supporting attachment and proliferation with as little as the first 10 domains (N10) [28].

In this study we sought to characterize endothelial progenitor cell interactions with recombinant human tropoelastin (rhTE). We used outgrowth endothelial progenitor cells (OECs), arising from cultured peripheral mononuclear cells [29], increasingly recognized to most closely conform to the definition of a ‘true EPC’ [29]. OECs are characterized by robust proliferative capacity and high sensitivity to angiogenic stimuli [30], incorporate into repairing endothelium, and can directly form vascular tubules [29,31,32]. In studies involving bone
marrow transplant patients, cultured OECs had the genotype of the donor rather than the recipient, consistent with a bone marrow origin for these cells [33]. OECs are herein referred to as EPCs.

We report that rhTE can support EPC attachment, spreading, and proliferation. Attachment and spreading occur via an integrin-mediated mechanism, involving but not limited to the αvβ3 integrin. Using truncation constructs of N-terminal domains we show that N25 and N18 can support EPC attachment and proliferation similar to full-length rhTE, while binding to N10 is poor.

**Materials and Methods**

**Materials**

Full-length recombinant human tropoelastin (rhTE) and N-terminal constructs representing the first 25 (N25), 18 (N18), and 10 (N10) domains (Fig 1) of rhTE were produced in a previously described *E. coli* expression system [34]. Human dermal fibroblasts (HDF; line GM3348) were obtained from Coriell Research Institute (Camden, NJ, USA). Primary human coronary artery smooth muscle cells (SMCs) were obtained from Cell Applications (San Diego, CA, USA). Fibronectin and vitronectin from human plasma, as well as calf skin collagen type 1 (Sigma) were used as controls. Anti-human integrin antibodies, αvβ3-clone LM609, α5β1-clone JBS5, and α2β1-clone BHA2.1 were obtained from Millipore. All other reagents were purchased from Sigma.

---

**Fig 1.** Schematic diagram showing full-length rhTE and constructs N18, N25 and N10. Key domain features are indicated.

doi:10.1371/journal.pone.0131101.g001
EPC isolation and culture

This study had ethics committee approval in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines (Sydney South West Area Health Service Ethics Approval #X06-0191). All study participants provided written informed consent. EPCs were isolated from 100–120 ml adult peripheral blood taken from healthy young male volunteers as previously described [31], collected into EDTA tubes [33]. Mononuclear cells (MNCs) were isolated using Lymphoprep, a density gradient separation. MNCs contained in the Buffy coat were aspirated and resuspended in EGM-2 media. 1–2x10^7 cells/ml were seeded onto 6-well type I rat tail collagen pre-coated plates. After 24 h, each well was gently washed to remove non-adherent cells. Media were exchanged daily for the first 7 days and then subsequently every second day. EPCs emerge as cobblestone shaped clusters of cells between days 14–21 [33]. EPC colonies reaching 80% confluence of the wells were carefully extracted and expanded in T25 flasks and subsequently moved to T175 flasks. All EPCs used were at passages 5–10.

Immunophenotyping

Confirmation of EPC phenotype was assessed using established flow cytometry methods, complemented with representative imaging [31]. For characterization using flow cytometry, OECs were detached, washed in PBS and resuspended in 0.5% BSA before blocking with FcR Blocking Reagent (Miltenyi Biotec) and staining with CD34-PerCP-Cy5.5, CD45-APC-Cy7, CD31-PE, CD14-APC, CD309(VEGFR2)-PE, CD54-PE for 30 min at 4°C (BD Pharmingen). The cells were then washed with PBS and stained with Zombie Aqua Viability dye (BioLegend) for 30 min at room temperature in PBS, before undergoing a final wash and resuspension in 0.5% BSA for reading on the FACSVersa (BD Biosciences, San Jose, California, USA). Unstained cells and fluorescence minus one (FMO) analyses was used for negative controls. Endothelial cell specific uptake of acetylated low density lipoprotein (Dil-Ac-LDL) and isothiocyanate-Ulex europaeus agglutinin I lectin (FITC-Ulex) binding was assessed. The presence of CD31 was also determined using a CD31/PECAM1 antibody (1:100 in antibody diluent; DAKO S3022). Fixed cells had their membranes permeabilized with 1% Triton-X-100 in PBS for 5 min, before blocking with peroxidase (30 min) and normal goat serum (1 h). HRP secondary antibody anti-mouse kit (DAKO K4000) was used for detection. Cell nuclei were counterstained with haematoxylin. 10 random fields of view per slide at 20X magnification were captured on a Zeiss Axiovision Imager Z2 and representative images shown. Exposures were equal for comparative images.

N-terminal specific ELISA

The relative amount of tropoelastin constructs bound to cell culture wells was determined with an ELISA. Triplicate wells were coated with 40 μg/mL of N10, N18, N25 or rhTE at 4°C overnight. Unbound tropoelastin was removed with three PBS washes. Non-specific antibody binding was blocked with 3% (w/v) BSA for 1h at room temperature, and excess BSA was washed off with PBS. Surface-bound tropoelastin was detected with a 1:5000 dilution of a custom-made mouse antibody specific against tropoelastin domain 6 (Abmart) for 1h at room temperature. Wells were washed three times with PBS and incubated with a 1:5000 dilution of goat anti-mouse IgG conjugated with horseradish peroxidase. Unbound secondary antibody was removed with four PBS washes, while the bound species was visualized by incubation with ABTS solution (1.04 mg/mL ABTS, 0.05% (v/v) H₂O₂, 10 mM CH₃COONa, 5 mM Na₂HPO₄) at 37°C for 1h. Sample absorbance were read at 405 nm with a plate reader, and subtracted by the absorbance of ABTS-only controls.
**Cell adhesion**

Fibronectin (FN) and collagen (CN) (5 μg/ml) were used as positive controls with concentrations based on dose-attachment/spreading titration assays. For both FN and CN, attachment and spreading of EPCs peaked at a concentration of 1.5 μg/ml; no significant increases were seen at concentrations up to 40 μg/ml (data not shown). A dose of 5 μg/ml for FN and CN was used to ensure plateau biological response. 100 μl of rhTE and truncated constructs were diluted in phosphate buffer saline (PBS), added to 96-well tissue culture plates and left overnight at 4°C. Unbound protein was aspirated and washed with PBS followed by addition for 1 h at room temperature of 150 μl 1% (w/v) heat-denatured bovine serum albumin (BSA). EPCs were trypsinized and adjusted to a cell density of 2–3 x 10^5 cells/ml in serum-free EGM-2 medium. Unbound BSA was removed from wells by PBS washing, then 100 μl of cells were added to each well, and allowed to attach for 60 min at 37°C. Non-adherent cells were washed off and adherent cells were fixed with 3.3% formaldehyde for 30 min. Attached cells were quantified following crystal violet staining; the stain was released with addition of 100 μl of 10% (w/v) acetic acid, and the absorbance was read at 580 nm. A standard curve was generated with defined cell numbers.

**Cell spreading**

Tissue culture plates were prepared in a similar manner to cell attachment. EPCs were harvested and made to a density of 1x10^5 cells/ml in serum-free EGM-2. 100 μl of cells were added to the wells and allowed to spread over 2 h at 37°C, after which 10 μl per well of 37% formaldehyde was directly added to the cells for 30 min. Using phase contrast microscopy, cells were considered unspread if they were small, round, and phase-bright. Spread cells were larger, phase dark with irregular cytoplasmic projections.

**Cell proliferation**

500 μl of protein (rhTE 40 μg/ml, vitronectin 0.5 μg/ml, CN 5 μg/ml and FN 5 μg/ml) and N-terminal domain constructs (40 μg/ml) in PBS were sterile-filtered (0.22 μm filters) and coated overnight at 4°C onto wells of 24-well plates. Wells were washed 3 times with 500 μl PBS, followed by blocking for 1 h with 600 μl of 1% BSA. Excess BSA was removed by washing with PBS. EPCs were prepared as described above except that cells were suspended in EBM-2 with 10% fetal calf serum to a density of 6x10^3 cells/ml. 1 ml of cell suspension was added to each well. Cells were left to proliferate for either 3 or 5 days, after which they were fixed with 3.3% formaldehyde and quantified using crystal violet [26].

**Inhibition of EPC adhesion**

The effect of lactose, heparan sulfate, and EDTA on EPC attachment was determined as described except that after BSA blocking 50 μl each at double-concentration were added to wells followed by an equal volume of 4x10^5 cells/ml of EPCs suspended in serum free EGM-2 medium.

**Divalent cation add-back**

After the wells were blocked with BSA, 50 μl of calcium (Ca^{2+}), magnesium (Mg^{2+}) or manganese (Mn^{2+}) was added at double-concentration and mixed with equal volume of 4x10^5 cells/ml EPCs resuspended in cation-free HEPES buffer.
Anti-integrin antibody assays
EPCs were suspended at 2×10^5 cells/ml density and aliquoted into microcentrifuge tubes. Integrin-blocking antibodies were added to the tubes to a concentration of 30 μg/ml and left at 37°C for 1 h. 100 μl of antibody and cell suspension was added to BSA-blocked wells coated with rhTE or N-terminal constructs. Adhesion, spreading and proliferation assays were as described.

Statistical Methods
Data are presented as mean ± SEM. Means were compared using 1-way analysis of variance (ANOVA) with pairwise comparisons (Tukey’s multiple comparisons test). Statistical significance was defined as p<0.05.

Results
Characterization of EPC phenotype
Consistent with previous studies [31], colonies of EPCs with a cobblestone morphology emerged from peripheral MNCs between days 14–21. Characterization by flow cytometry suggests that the OECs used in these experiments are of endothelial lineage (CD31 99.7±0.1%; CD54 95.4±0.1%; VEGFR2 96.3±0.1% positive) with no hematopoietic cells present (CD45 0.43±0.03%; CD14 0.20±0.03% negative). A subset of cells also still express CD34 (25.2±0.5%), a progenitor cell marker. In contrast to human dermal fibroblasts, EPCs displayed characteristic Ulex binding and incorporation of acLDL, and stained positively for CD31 (Fig 2).

Tropoelastin enhances EPC attachment, spreading and proliferation
EPC attachment to rhTE was concentration dependent, reaching 57±1% at 10 μg/ml, but a maximum of 67±1% at 40 μg/ml, the highest concentration tested (Fig 3A). For context, attachment of human dermal fibroblasts and human coronary artery smooth muscle cells (SMC) to rhTE was also examined in the same assay. Fibroblast attachment was greatest, reaching 83±2% at the highest tropoelastin concentration, in contrast to SMCs which only had 39±1% of cells attached. rhTE also enhanced EPC spreading in a concentration-dependent manner reaching 54±3% at 25 μg/ml and 58±2% at 40 μg/ml. Spreading was not significantly different between 25 and 40 μg/ml coating concentrations (p = 0.92, Fig 3B).

EPC attachment was higher on FN (5 μg/ml) and CN (5 μg/ml) at 77±3% and 73±1%, respectively (p<0.01 vs. rhTE, data not shown). EPC spreading was also greater on FN (77±3%) and CN (82±6%, p<0.01 vs. rhTE), demonstrated in representative phase contrast images (Fig 3C).

For cell proliferation studies, EPCs were seeded on rhTE and compared to vitronectin, collagen (CN) and fibronectin (FN) coated surfaces. Cells were quantified with crystal violet staining and expressed as relative absorbance at 570 nm. On day 3, EPC proliferation on rhTE was not significantly different to FN (p<0.05) and collagen (p<0.01) did reach significance compared to rhTE, but were indistinguishable from each other. By day 5, EPCs grown on rhTE had increased 152±4%, relative to day 3. EPCs on vitronectin, collagen and FN were all significantly more abundant than on rhTE.

EPC binding to tropoelastin involves integrin αvβ3
Cells interact with tropoelastin through three main mechanisms, i) cell surface glycosaminoglycans (GAGs) ii) transmembrane elastin binding protein, and iii) integrins. These interactions are inhibited in vitro by administration of heparan sulfate, lactose and EDTA respectively [26]. We explored the nature of the interaction between EPCs and rhTE using this approach. Heparan sulfate up to 10 μg/ml caused no reduction in EPC attachment to
Fig 2. OEC characterization by flow cytometry. A) Stained cells are shown as blue histograms, while unstained controls are shown in black. The percentage of positive cells is shown in the top right of each graph. The OECs are CD34/31/54/VEGFR2 positive and CD45/14 negative. B) Representative images of the binding of isothiocyanate-Ulex europaeus agglutinin I lectin binding (ULEX), uptake of acetylated low density lipoprotein (AcLDL) and staining for CD31 by EPCs (bottom row of panel) but not by fibroblasts (top row of panel). Together, these results are indicative of a positive endothelial cell phenotype.

doi:10.1371/journal.pone.0131101.g002
The inclusion of α- and β-lactose up to 10 mM also had no effect on EPC adhesion. In contrast, we saw a progressive reduction of EPC adhesion with increasing concentrations of EDTA. At 10 mM EDTA, there was an 81±3% (p<0.001) reduction in attachment (Fig 4A), suggesting an integrin-mediated interaction.

Fig 3. Cell binding to recombinant human tropoelastin. (A) Relative attachment of human dermal fibroblasts, EPCs, and human coronary artery smooth muscle cells (SMC) to increasing concentrations of tropoelastin. (B) The percentage of spread EPCs on increasing concentrations of tropoelastin. (C) Phase contrast microscopy of spreading EPCs on BSA-blocked wells, tropoelastin (rhTE), collagen (CN), fibronectin (FN). Images were taken at 10x magnification. (D) EPC proliferation on days 3 and 5, respectively. Error bars represent S.E.M. of triplicate measurements.

doi:10.1371/journal.pone.0131101.g003
Divalent cation add-back experiments provided further evidence of integrin binding [35]. In the absence of cations, EPC adhesion was similar to background levels, while a concentration-dependent increase in EPC attachment was evident in the presence of manganese. Full recovery was seen with 0.25 mM manganese. In contrast, there was only a small increase in EPC attachment with calcium up to 0.5 mM. Magnesium had an intermediate effect (Fig 4B).

Anti-α5β1 and anti-α2β1 integrin blocking antibodies were found to have no effect on EPC adhesion, while anti-αvβ3 antibodies led to a 39±3% (p < 0.001) reduction in EPC attachment (Fig 4C and D).

Fig 4. Mechanism of EPC attachment to rhTE. (A) EPCs attached to 40 μg/ml rhTE in the presence of α-lactose, β-lactose, heparan sulfate, or EDTA. (B) Attachment of EPCs to 40 μg/ml rhTE in the presence of Ca²⁺, Mg²⁺, or Mn²⁺. (C) and (D) Inhibition of EPC attachment and spreading on 40 μg/ml rhTE using antibodies to integrins α2β1, α5β1, and αvβ3. Error bars represent S.E.M. of triplicate measurements.

doi:10.1371/journal.pone.0131101.g004
(Fig 4C). A similar effect on EPC spreading was evident with the inclusion of anti-αVβ3 antibody leading to a 56±10% (p<0.01) decrease in cell spreading. Anti-α2β1 and -α5β1 antibodies had no impact on EPC spreading (Fig 4D). No effect on proliferation was observed in the presence of integrin blocking antibodies (S1 Fig).

**EPC attachment, spreading, and proliferation are supported by N-terminal domains of tropoelastin**

The C-terminus of rhTE is known to be important for adhesion of fibroblasts [26,36]. An additional contribution from the mid-domain regions 17/18 has only been recently described [27]. In contrast, endothelial cell binding to rhTE can be supported by the first 10 N-terminal domains [28]. In this study we sought to determine a preferred binding region for EPCs to rhTE. We expressed and purified truncation constructs of rhTE, spanning regions from the N-terminus to domains 25 (N25), 18 (N18), and 10 (N10). An ELISA specific for domain 6 of tropoelastin showed no significant differences in the relative amount of each present on tissue culture plastic (S2 Fig). N25 supported 38±2% attachment of EPCs at a concentration of 20 μg/ml and up to 43±3% at 40 μg/ml. A comparable level of 38±2% attachment was seen on N18 at 20 μg/ml, and up to 42±5% at 40 μg/ml (N25 vs. N18, p = 0.09) (Fig 5A). EPC spreading was comparable on N25 and N18 at 56±2% and 57±1%, respectively (N25 vs. N18, 40 μg/ml, p = 0.92) (Fig 5B). When compared to full length rhTE EPC spreading on N25 and N18 constructs was similar (rhTE vs N25 and N18, P = 0.81 and P = 0.94, respectively).

Proliferation of EPCs on N18 and N25 on day 3 was not significantly different to each other or rhTE, but less than FN (p<0.01), CN (p<0.05) and vitronectin (p<0.01). (Fig 5C). On day 5, proliferation increased on rhTE (117±4%), N18 (91±3%) and N25 (86±3%), relative to day 3 and again were not significantly different to each other. FN and CN remained statically superior, but vitronectin was equivalent at this time. In contrast, N10 displayed poor EPC interaction, even with an increased concentration up to 100 μg/ml. A maximum cell attachment of 11 ±2% (Fig 5E) and spreading of 28±2% (Fig 5F) was observed.

As for rhTE, we investigated the mechanism of interaction between N25 and N18 constructs with EPCs. No appreciable effect on cell attachment was seen in the presence of α-lactose, β-lactose, and heparan sulfate. However, the addition of EDTA led to a 65±2% (p<0.0001), and 76±5% (p<0.001) reduction in attachment to N25 and N18, respectively (Fig 6A and 6B). When divalent cations were re-introduced to cation-free buffer, a dose-dependent full recovery of EPC attachment to both N25 and N18 was seen with manganese (Fig 6C and 6D), but not for magnesium or calcium, as expected for an integrin interaction. Anti-αVβ3 antibody led to a 45±4% (p<0.001) and 42±14% (p<0.05) decrease in EPC spreading on N25 and N18, respectively (Fig 6E and 6F), while anti-α5β1 had no effect. These results collectively establish an integrin-based mode of EPC interaction with N25 and N18 that involves αVβ3.

**Discussion**

In this study we sought to characterize the interaction of EPCs with recombinant human tropoelastin. We found that EPCs in the form of outgrowth endothelial cells, attached to and spread on rhTE, similar to previous findings for human umbilical vein endothelial cells [19]. The level of attachment of EPCs was intermediate, between fibroblasts, well characterized to adhere strongly to rhTE, and SMCs, which were expected to have low adhesive capacity. FN and CN demonstrated higher levels of cell adhesion, consistent with previous studies [37,38]. However, the role of FN and CN for clinical applications is hindered by their inherent thrombogenicity, platelet activation [39,40], and chemotraction for VSMCs [19]. Proliferation of EPCs on rhTE was statistically less than vitronectin, CN and FN at days 3 and 5 but was
Fig 5. EPC attachment (A) and spreading (B) on tropoelastin constructs N25 and N18. C) and (D) Proliferation of EPCs on N25 and N18 constructs, on days 3 and 5, respectively. Values were normalized to proliferation on collagen. Error bars represent S.E.M. of triplicate measurements. EPC attachment (E) and spreading (F) to tropoelastin construct N10. Attachment and spreading assays on N10 constructs was done on the same cell plates as for N25 and N18 constructs. Results are expressed separately to highlight higher maximal concentrations of N10 used. Error bars represent S.E.M. of triplicate measurements.

doi:10.1371/journal.pone.0131101.g005
Fig 6. Mechanism of EPC attachment to truncated tropoelastin constructs. (A) and (B) EPCs attached to 40 μg/ml N25 and N18 respectively, in the presence of α-lactose, β-lactose, heparan sulfate or EDTA. (C) and (D) Attachment of EPCs to 40 μg/ml N25 and N18, respectively, in the presence of Ca\(^{2+}\), Mg\(^{2+}\), or Mn\(^{2+}\). (E) and (F), Inhibition of EPC spreading on 40 μg/ml N25 and N18 respectively, using antibody that inhibits binding to integrin α\(\text{v}\)β\(\text{3}\). Error bars represent S.E.M. of triplicate measurements.

doi:10.1371/journal.pone.0131101.g006
substantial overall. These findings establish that rhTE supports EPC attachment, spreading and proliferation.

The elastin binding protein [41,42] mediates the chemotactic properties of elastin but cell attachment is increasingly thought to be through alternate mechanisms. The C-terminus is known to be a strongly cell adhesive region in tropoelastin. Bovine chondrocytes adhere to the C-terminal 29–36 domains of bovine elastin through surface glycosaminoglycans (GAGs) [25] whereas human dermal fibroblasts interact with rhTE through the C-terminal motif (GRKRK) using an integrin-based mechanism [26]. A second fibroblast binding site comprising domains 17 and 18 also appears to be integrin-mediated [27]. Human umbilical vein endothelial cells however bind preferentially to the N-terminus [28], suggesting the possibility of differential binding to tropoelastin dependent on cell type.

We first identified that the interaction between human EPCs and rhTE is likely integrin mediated. Inhibitor studies indicated that while EPC adhesion to rhTE was not through the elastin binding protein or cell surface GAGs, multiple experiments support an integrin-based mechanism. These included both a dose-dependent decrease in EPC attachment to rhTE with increasing concentrations of EDTA and a dependence on divalent cations and specifically manganese. Manganese induces strong ligand affinity in integrin $\alpha V \beta 3$ [43]. Using an inhibitory antibody to integrin $\alpha V \beta 3$ we saw a decrease in both EPC adhesion and spreading on rhTE. The extent of inhibition was less than that previously seen with fibroblasts [26], but consistent with levels seen for mature endothelial cells, indicating that additional integrins may be involved [44]. Antibodies to $\alpha 2 \beta 1$ and $\alpha 5 \beta 1$ had no effect on either EPC attachment or spreading. $\alpha 2 \beta 1$ typically interacts with CN via GFOGER [45] and $\alpha 5 \beta 1$ binds FN through an RGD motif [46]; rhTE contains neither motif [47].

Conflicting information exists for the capacity of the N-terminus to support cell attachment [19,25]. Recently N-terminal constructs of rhTE were shown to support the adhesion and growth of mature endothelial cells [28] indicating that, in addition to the C-terminus, other cell binding site(s) are present in rhTE. In this study we used progressively shorter truncation domains of the N-terminus to investigate support for EPC adhesion in each region.

The N25 construct accounted for the largest proportion of cell attachment (68±5%, $p<0.001$ of full length rhTE) and showed spreading (93±3%) that was comparable to that seen on full-length rhTE. Further truncation to the shorter N18 construct however presented comparable attachment, spreading and proliferation to N25, suggesting a model where the region between domains 18 and 25 is not required for cell adhesion. The even shorter N10 construct consistently showed reduced cell attachment and spreading that was only marginally higher than background BSA levels, even at high concentrations. Together these results suggest that EPCs bind a region bracketed by domains 10 and 18 of rhTE, consistent with the additional binding site recently described for fibroblasts [27].

In conclusion, rhTE supports EPC binding via an integrin mechanism involving $\alpha 2 \beta 1$ and interacting with tropoelastin between domains 10 and 18. These findings suggest that rhTE and constructs containing domains 10–18 may have the potential to enhance EPC directed endothelial repair.

**Supporting Information**

**S1 Fig.** EPC proliferation on rhTE in the presence of antibodies to integrins $\alpha 2 \beta 1$, $\alpha 3 \beta 1$, and $\alpha V \beta 3$, applied at the time of cell seeding. These antibodies had no significant effect on EPC proliferation relative to the no antibody rhTE control. Error bars represent S.E.M. of triplicate measurements.

(TIFF)
S2 Fig. ELISA specific for domain 6 of tropoelastin showing no significant differences in the relative amount of full-length rhTE and each of N25, N18 and N10. Error bars represent S.E.M. of triplicate measurements. (TIF)

Acknowledgments
We acknowledge funding from the Australian Research Council (A.S.W.), National Health and Medical Research Council (APP1033079 and APP1039072; M.K.C.N. and A.S.W.) and National Institutes of Health (EB014283; A.S.W.). The authors declare no conflict of interest in this work. The authors also acknowledge the facilities as well as scientific and technical assistance at the Australian Centre for Microscopy and Microanalysis.

Author Contributions
Conceived and designed the experiments: YY SGW DVB DSC ASW MKCN. Performed the experiments: YY PLM DVB GSCY MAH GCY ECF LLD. Analyzed the data: YY SGW DVB ASW MKCN. Contributed reagents/materials/analysis tools: YY SGW DVB MAH KHC HH DSC ASW MKCN. Wrote the paper: YY SGW MKCN.

References
1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967. PMID:9020076
2. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. N Engl J Med. 2005; 353: 999–1007. PMID:16148285
3. Gunsilius E. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Adv Exp Med Biol. 2003; 522: 17–24. PMID:12674207
4. Crosby JR, Kaminski WE, Schatteman G, Martin PJ, Raines EW, Seifert RA, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000; 87: 728–730. PMID:11055974
5. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol. 2010; 55: 1553–1565. doi:10.1016/j.jacc.2009.10.070 PMID:20378071
6. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000; 97: 3422–3427. PMID:10725398
7. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001; 7: 430–436. PMID:11283669
8. Waller BF. Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease. Hum Pathol. 1987; 18: 476–484. PMID:2952575
9. Lau AK, Leichtweis SB, Hurme P, Mashima R, Hou JY, Chaufour, et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation. 2003; 107: 2031–2036. PMID:12681995
10. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med. 1996; 47: 315–331. PMID:8712785
11. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998; 92: 362–367. PMID:9657732
12. Petit A, Wang HT, Girard-Lauriault PL, Wertheimer MR, Antoniou J, Mwale F. Novel insights into the mechanism of decreased expression of type X collagen in human mesenchymal stem cells from patients with osteoarthritis cultured on nitrogen-rich plasma polymers: implication of cyclooxygenase-1. J Biomed Mater Res A. 2010; 94: 744–750. doi:10.1002/jbm.a.32739 PMID:20225218
13. Fukuda D, Enomoto S, Shirakawa I, Nagai R, Sata M. Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment. Eur J Pharmacol. 2009; 612: 87–92. doi:10.1016/j.ejphar.2009.04.006 PMID:19371799
14. Yoshioka T, Takahashi M, Shiba Y, Suzuki C, Morimoto H, Izawa A, et al. Granulocyte colony-stimulating factor (G-CSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice. Cardiovasc Res. 2006; 70: 61–69. PMID: 16448633

15. Gulati R, Jevremovic D, Peterson TE, Witt TA, Kieppe LS, Mueske CS, et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation. 2003; 108: 1520–1526. PMID: 12952850

16. Rosenzweig A. Cardiac Cell Therapy—Mixed Results from Mixed Cells. N Engl J Med. 2006; 355: 1274–1277. PMID: 16990391

17. Wise SG, Waterhouse A, Michael P, Ng MK. Extracellular matrix molecules facilitating vascular biointegration. J Funct Biomater. 2012; 3: 569–587.

18. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, et al. Elastin is an essential determinant of arterial morphogenesis. Nature. 1998; 393: 276–280. PMID: 9607766

19. Williamson MR, Shuttleworth A, Canfield AE, Black RA, Kielty CM. The role of endothelial cell attachment to elastic fibre molecules in the enhancement of monolayer formation and retention, and the inhibition of smooth muscle cell recruitment. Biomaterials. 2007; 28: 5307–5318. PMID: 17850863

20. Robinet A, Fahem A, Cauchard J-H, Huet E, Vincent L, Lorimier S, et al. Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci. 2005; 118: 343–356. PMID: 15632106

21. Waterhouse A, Wise SG, Ng MK, Weiss AS. Elastin as a Nonthrombogenic Biomaterial. Tissue Eng Part B. 2011; 17: 93–99. doi: 10.1089/ten.TEB.2010.0432 PMID: 21166482

22. Yin Y, Wise SG, Nosworthy NJ, Waterhouse A, Bax DV, Youssef H, et al. Covalent immobilisation of tropoelastin on a plasma deposited interface for enhancement of endothelialisation on metal surfaces. Biomaterials. 2009; 30: 1675–1681. doi: 10.1016/j.biomaterials.2008.11.009 PMID: 19157535

23. Waterhouse A, Yin Y, Wise SG, Bax DV, McKenzie DR, Bilek MMM, et al. The immobilization of recombinant human tropoelastin on metals using a plasma-activated coating to improve the biocompatibility of coronary stents. Biomaterials. 2010; 31: 8332–8340. doi: 10.1016/j.biomaterials.2010.07.062 PMID: 20708259

24. Almine JF, Bax DV, Miltheux SM, Nivison-Smith L, Rnjak J, Waterhouse A, et al. Elastin-based materials. Chem Soc Rev. 2010; 39: 3371–3379. doi: 10.1039/b919452p PMID: 20449520

25. Broekelmann TJ, Kozel BA, Ishibashi H, Werneck CC, Keeley FW, Zhang L, et al. Tropoelastin interacts with Cell-surface Glycosaminoglycans via Its COOH-terminal Domain. J Biol Chem. 2005; 280: 40939–40947. PMID: 16192266

26. Bax DV, Rodgers UR, Bilek MMM, Weiss AS. Cell adhesion to tropoelastin is mediated via the α-terminal GRKRK motif and integrin αvβ3. J Biol Chem. 2009; 284: 28616–28623. doi: 10.1074/jbc.M109.017525 PMID: 19617625

27. Lee P, Bax DV, Bilek MM, Weiss AS. A novel cell adhesion region in tropoelastin mediates attachment to integrin αvβ5. J Biol Chem. 2014; 289: 1467–1477. doi: 10.1074/jbc.M113.518381 PMID: 24293364

28. Hiob MA, Wise SG, Kondyurin A, Waterhouse A, Bilek MM, Ng MK, et al. The use of plasma-activated covalent attachment of early domains of tropoelastin to enhance vascular compatibility of surfaces. Biomaterials. 2013; 34: 7584–7591. doi: 10.1016/j.biomaterials.2013.06.036 PMID: 23863453

29. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007; 109: 1801–1809. PMID: 17053059

30. Zheng CL, Cui FZ, Meng B, Ge J, Liu DP, Lee I-S, et al. Hemocompatibility of C—N films fabricated by ion beam assisted deposition. Surf Coat Tech. 2005; 193: 361–365.

31. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol. 2008; 51: 660–668. doi: 10.1016/j.jacc.2007.09.059 PMID: 18261686

32. Dekker A, Reitsma K, Beugeling T, Bantjes A, Feijen J, Vanaken WG, et al. Adhesion of endothelial cells and adsorption of serum proteins on gas plasma-treated polytetrafluoroethylene. Biomaterials. 1991; 12: 130–138. PMID: 1878448

33. Lin Y, Weisflog DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000; 105: 71–77. PMID: 10619863

34. Wu WJ, Vrhovski B, Weiss AS. Glycosaminoglycans mediate the coacervation of human tropoelastin through dominant charge interactions involving lysine side chains. J Biol Chem. 1999; 274: 21719–21724. PMID: 10419484
35. Mould AP, Garratt AN, Puzon-McLaughlin W, Takada Y, Humphries MJ. Regulation of integrin function: evidence that bivalent-cation-induced conformational changes lead to the unmasking of ligand-binding sites within integrin alpha5 beta1. Biochem J. 1998; 331: 821–828. PMID: 9560310

36. Brockmann MA, Gutenson K, Bau J, Kuehnl P, Meinertz T, Nienaber C, et al. Influence of heparin coating of coronary stents and ex vivo efficacy of different doses of acetylsalicylic acid and ticlopidine in a pulsed floating model of recirculating human plasma. Platelets. 2002; 13: 443–449. PMID: 1248777

37. Ruoslahti E. Fibronectin in cell adhesion and invasion. Cancer Metastasis Rev. 1984; 3: 43–51. PMID: 6324988

38. Heino J. The collagen family members as cell adhesion proteins. Bioessays. 2007; 29: 1001–1010. PMID: 17876790

39. Cho J, Mosher DF. Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood. 2006; 107: 3555–3563. PMID: 16391013

40. Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn ML. GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. Blood. 2005; 106: 1268–1277. PMID: 15886326

41. Mecham RP, Hinek A, Entwistle R, Wrenn DS, Griffin GL, Senior RM. Elastin binds to a multifunctional 67-kilodalton peripheral membrane protein. Biochemistry. 1989; 28: 3716–3722. PMID: 2546580

42. Blanchevoye C, Floquet N, Scandolera A, Baud S, Maurice P, Bocquet O, et al. Interaction between the elastin peptide VGVAPG and human elastin binding protein. J Biol Chem. 2013; 288: 1317–1328. doi: 10.1074/jbc.M112.419929 PMID: 23166321

43. Smith JW, Cheresh DA. Labeling of integrin alpha v beta 3 with 58Co(III). Evidence of metal ion coordination sphere involvement in ligand binding. J Biol Chem. 1991; 266: 11429–11432. PMID: 1711032

44. Wilson BD, Gibson CC, Sorensen LK, Guilhermier MY, Clinger M, Kelly LL, et al. Novel approach for endothelializing vascular devices: understanding and exploiting elastin-endothelial interactions. Ann Biomed Eng. 2011; 39: 337–346. doi: 10.1007/s10439-010-0142-z PMID: 20737290

45. Khew ST, Zhu XH, Tong YW. An integrin-specific collagen-mimetic peptide approach for optimizing Hep3B liver cell adhesion, proliferation, and cellular functions. Tissue Eng. 2007; 13: 2451–2463. PMID: 17596119

46. Takagi J, Strokovich K, Springer TA, Walz T. Structure of integrin [alpha]5[beta]1 in complex with fibronectin. EMBO J. 2003; 22: 4607–4615. PMID: 12970173

47. Rodgers UR, Weiss AS. Cellular interactions with elastin. Pathol Biol. 2005; 53: 390–398. PMID: 16085115